Cadrenal Therapeutics, Inc. 8-K

What Happened
Cadrenal Therapeutics, Inc. (CVKD) announced on April 30, 2026 that it completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration and received guidance on key elements of a pivotal Phase 3 trial for CAD-1005, its investigational first‑in‑class 12‑lipoxygenase (12‑LOX) inhibitor for heparin‑induced thrombocytopenia (HIT). After considering FDA feedback, the company plans to advance directly to a randomized, blinded, placebo‑controlled Phase 3 study evaluating CAD-1005 added to current standard of care.

Key Details

• Meeting and announcement date: April 30, 2026.
• Planned pivotal Phase 3 design: randomized, blinded, placebo‑controlled, CAD-1005 added to standard of care.
• Trial scale: approximately 120 patients across up to 50 clinical centers worldwide.
• Primary endpoint guidance: new or worsening thrombotic events; FDA provided input on protocol design, study population, dosing, background therapy, exposure and safety database.
• Regulatory timeline: trial intended to support a projected New Drug Application (NDA) submission in 2029.

Why It Matters
This filing signals regulatory progress—FDA feedback supports a direct move to a pivotal Phase 3 registration study, which can materially advance CAD-1005 toward potential approval. For investors, the planned randomized, blinded, placebo‑controlled design and a relatively small global enrollment (~120 patients) define a clear development path and an estimated NDA timeline (2029). The update reduces uncertainty around trial design but does not provide clinical or financial results; risks and outcomes will hinge on upcoming trial execution and data.